HHS OIG Health Care Fraud Enforcement Brief
Headline
CVS Pharmacy agrees to pay $315 million to resolve opioid prescription and false claims allegations
Executive Summary
The Department of Justice announced on October 13, 2026 that CVS Pharmacy Inc. and its related corporate entities have agreed to pay $315 million. The settlement resolves allegations that CVS illegally filled opioid and controlled-substance prescriptions and submitted false claims to Medicare and other federal healthcare programs.
Bottom Line
CVS Pharmacy Inc. and its related corporate entities agree to pay $315 million to resolve DOJ allegations of illegal opioid and controlled-substance prescription filling under the Controlled Substances Act and false claims submissions to Medicare and other federal healthcare programs under the False Claims Act. The conduct period runs from October 17, 2013 through December 2, 2025. Both criminal and civil actions are part of the resolution. Cresthaven reading: the settlement's dual-statute structure and multi-payer scope place controlled-substance dispensing compliance and federal program billing accuracy at the center of active DOJ enforcement for pharmacy operators.
Key Regulatory Signals
- Settlement Scope and Amount: CVS Pharmacy Inc. and its related corporate entities have agreed to pay $315 million to resolve allegations covering conduct from October 17, 2013 through December 2, 2025. The resolution encompasses both criminal and civil actions.
- Dual Statutory Basis: The allegations rest on two distinct legal frameworks: the Controlled Substances Act, for illegally filling prescriptions for opioids and other controlled substances, and the False Claims Act, for submitting claims for those invalid prescriptions to Medicare and other federal healthcare programs.
- Federal Healthcare Program Exposure: The false claims allegations extend beyond Medicare to other federal healthcare programs, meaning the settlement's scope covers multiple government payers. Cresthaven reading: pharmacy operators and pharmacy benefit managers billing federal healthcare programs face an active DOJ enforcement posture on controlled-substance dispensing compliance.
- Criminal and Civil Dual Track: The DOJ lists the enforcement types for this action as criminal and civil actions.
Regulatory Delta
DOJ opioid enforcement against large pharmacy chains follows an established pattern. The 2022 settlement with Walmart and the 2023 actions against Walgreens and Rite Aid set the precedent for False Claims Act liability tied to controlled-substance dispensing failures.
The conduct period covered by this settlement extends through December 2, 2025, well past the peak opioid-crisis years and into a period when dispensing compliance frameworks were already in place. That timing expands the liability window beyond what earlier enforcement actions addressed.
Materiality Classification
MEDIUM — Single-firm settlement with no explicit sweep or continuation language from DOJ, but the dual-statute structure and multi-payer scope carry directional enforcement signal for pharmacy operators billing federal healthcare programs on controlled-substance claims.
Intelligence Outlook
Monitor DOJ and HHS-OIG press releases for additional pharmacy-sector enforcement actions involving controlled-substance dispensing and False Claims Act liability.